BlackRock Institutional Trust’s Karyopharm Therapeutics KPTI Stock Holding History

BlackRock Institutional Trust’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.23M	Buy	37,092 +1,153	+3%	+$156K	﹤0.01%	2711
2016 Q3	$5.25M	Buy	35,939 +551	+2%	+$66.2K	﹤0.01%	2671
2016 Q2	$3.56M	Buy	35,388 +1,093	+3%	+$142K	﹤0.01%	2819
2016 Q1	$4.59M	Sell	34,295 -363	-1%	-$40.1K	﹤0.01%	2707
2015 Q4	$6.89M	Buy	34,658 +666	+2%	+$144K	﹤0.01%	2550
2015 Q3	$5.37M	Buy	33,992 +3,084	+10%	+$825K	﹤0.01%	2676
2015 Q2	$12.6M	Buy	30,908 +2,568	+9%	+$1.11M	﹤0.01%	2250
2015 Q1	$13M	Buy	28,340 +13,735	+94%	+$5.92M	﹤0.01%	2224
2014 Q4	$8.2M	Buy	14,605 +5,204	+55%	+$2.96M	﹤0.01%	2475
2014 Q3	$4.93M	Buy	9,401 +503	+6%	+$284K	﹤0.01%	2695
2014 Q2	$6.21M	Buy	8,898 +3,500	+65%	+$1.63M	﹤0.01%	2673
2014 Q1	$2.5M	Sell	5,398 -2,846	-35%	-$1.44M	﹤0.01%	3072
2013 Q4	$2.83M	Buy	+8,244	New	+$2.28M	﹤0.01%	3022

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Institutional Trust's KPTI Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Karyopharm Therapeutics (KPTI) stake by 3.2% in Q4 2016, buying an estimated $156K and bringing the position to 37,092 shares worth $5.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

BlackRock Institutional Trust first reported a position in KPTI in Q4 2013 and has held it in 13 quarters since. The position peaked at $13M in Q1 2015. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

BlackRock Institutional Trust held 37,092 shares of Karyopharm Therapeutics worth $5.23M as of Q4 2016.
BlackRock Institutional Trust bought 1,153 Karyopharm Therapeutics shares in Q4 2016, an estimated $156K.
Karyopharm Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2711 holding.
BlackRock Institutional Trust first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 13 quarters since.
BlackRock Institutional Trust's Karyopharm Therapeutics position peaked at $13M in Q1 2015.
86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.